

MARCH 2023
PRIVATE &
CONFIDENTIAL

acquiring and advancing
Artificial Intelligence/Machine Learning
technologies addressing urgent societal needs

INVESTOR PRESENTATION



CSE: AIML
OTCQB: AIMLF
FWB: 42FB

Disclaimer



CSE: AIML
OTCQB: AIMLF
FWB: 42FB

This information memorandum ("IM") has been prepared by AI/ML Innovations Inc. (AIML) All references to AIML in this Disclaimer and IM also refer and apply to Health Gauge Inc (or "HG") and Tech2Heal SAS

This IM is for information purposes only and does not constitute an offer to sell or a solicitation to buy the securities referred to herein.

This IM is not intended to provide and does not purport to provide the basis for any investment or credit decision or any other risk evaluation. No part of this IM constitutes a recommendation, offer, invitation or solicitation, or a representation by or on behalf of AIML with any recipient of this IM (each a "Recipient") or with any other person. Further, this IM does not provide and does not purport to provide all the information that a Recipient may require for the purpose of evaluating AIML. For example, information on certain matters has not been included in this IM for reasons of commercial sensitivity, even though such information may be material to a Recipient. This IM and its contents are confidential. Each Recipient must not reproduce, transmit or otherwise make available any part of this IM without the prior written consent of AIML. The material herein and any access to it is intended only for a person or entity that is a Sophisticated or Professional Investor as defined under applicable Canadian securities laws.

No representation or warranty (whether express or implied) is given by or on behalf of AIML (and its directors, officers, employees, agents and advisers): as to the accuracy, completeness, currency or reliability of the material contained in this IM; that reasonable care has been taken in compiling or preparing the material contained in this IM; or that the material contained in this IM is the totality of the information that may be required or expected in order to evaluate AIML. To the maximum extent permitted by law, AIML (and its directors, officers, employees, agents and advisers) disclaim all liability for any loss or damage suffered or incurred by any Recipient as a result of or arising out of any Recipient using or placing any reliance on the material contained in this IM. Each Recipient will undertake their own independent investigation and assessment of the assets, business, liabilities and prospects of Salu and will seek appropriate professional advice. The material contained in this IM includes statements, estimates and projections provided by, or on behalf of, AIML with respect to the future performance of the company or which are otherwise of a forward-looking nature ("Forward-Looking Information"). Such Forward-Looking Information reflect various assumptions concerning anticipated results, which are not necessarily indicative of future performance which may be significantly less favourable than is implied by the Forward-Looking Information. Accordingly, without limiting the generality of anything else in this IM, no warranty or representation (whether express or implied) is made as to the accuracy, completeness or reasonableness of any Forward-Looking Information. Any Forward-Looking Information should not be relied upon as indicative of future value or as a guarantee of value or future results. There is no guarantee that any estimates or forecasts in any Forward-Looking Information will be achieved. Further, Salu disclaims any intention or obligation to update or revise any Forward-Looking Information whether as a result of new information, future events or otherwise, except to the extent required by applicable laws.

This IM is governed by the laws of Canada. Each Recipient submits to the non-exclusive jurisdiction of courts exercising jurisdiction there and waive any right to claim that those courts are an inconvenient forum. All figures in this IM are in CAD unless otherwise stated. This presentation is not an offer of the securities for sale in the United States. The securities have not been registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an exemption from registration. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful.



PRIVATE & CONFIDENTIAL



Why AI Matters in Healthcare:

AI/ML technologies serve to positively impact healthcare delivery, putting data to work for improved outcomes.

WHO BENEFITS FROM AI?

ORGANIZATIONS (healthcare providers, employers, benefits providers, insurance companies)

Benefits include improved healthcare delivery (greater accuracy, innovation, cost-effectiveness, speed and/or volume of delivery).

INDIVIDUALS (employees, patients, consumers)

Benefits include: superior information; better access to care; more personalized experience; greater overall control over one's health decisions; faster service.

Who is AM/AL Innovations Inc?



WHAT WE ARE BUILDING:

a portfolio of transformative AI/ML-powered, health-tech companies addressing urgent societal needs.


HOW WE DO THIS:

through synergistic acquisition of emerging B2B-focused companies with proprietary processes and SaaS subscription-based revenue models.

OUR OPPORTUNITY:

to drive transformative healthcare management solutions and precision support delivery across the health continuum - from wellness and prevention to treatment, monitoring and recovery.

Investing in Tomorrow's Technology - Today



Company Highlights

- + Focused on AI-driven solutions in the digital wellness marketplace
- + 2 completed acquisitions - in digital health monitoring and digital mental health/DTx spaces
- + Experienced team with 100+ years combined relevant experience
- + B2B and B2B2C SaaS business models with multiple revenue streams

Six Reasons to Invest in AI/ML Innovations Inc. Now:

- + Huge revenue potentials in multiple streams
- + Substantial market cap discount to industry peers
- + Reoccurring revenue model (SaaS subscriptions)
- + Diversified across synergistic product lines
- + A global operating footprint
- + Robust M&A pipeline



CSE: AIML
OTCQB: AIMLF
FWB: 42FB

AI/ML's Investments – focus

chronic disease monitoring and mental health



Health Gauge is transforming the \$245 billion global digital health monitoring market via its *proprietary combination of digital wearable health monitoring devices, AI-based software, and a cloud computing platform* which combine to help care-givers, patients and healthcare professionals access and utilize relevant health data effortlessly.




Tech2Heal is a digital healthcare innovator with a basket of health-tech products and services designed to improve an individual's mental well-being by utilizing a unique blend of *proprietary digital assets and remote live counselling*.

Our Investment in Digital Health Monitoring



“Our patented solution is a bespoke personal health monitoring & management system, combining the best-in-class wearable health monitors with AI-driven software tools”




**AI/ML
INNOVATIONS
INC**

{100% owned by AIML

Our Investment in Digital Mental Health and DTx



“Tech2Heal is a Paris, France based healthcare innovator specializing in digital health technologies with the objective of creating a compassionate, collaborative and patient-centered healthcare ecosystem.”



**AI/ML
INNOVATIONS
INC**

{ 9.4% of Tech2Heal Global market
70% of N. A. rights

OUR TEAM – management and board of directors



Tim Daniels, B. Comm. (Finance) Executive Chairman, AI/ML Innovations Inc

Over the past 25 years, Tim has held the positions of Chairman, Director, CEO and CFO for several Canadian and US-based, private and publicly traded technology, biomedical and strategic hi-tech mineral companies. Tim's extensive management experience includes a focus on corporate finance, strategic planning, project development and corporate governance matters. Tim has led in the raising of many tens of millions of dollars for various projects and companies over the course of his career.

Randy Duguay, P.Eng, M.Eng CEO & Director, AI/ML Innovations Inc and Health Gauge

Randy was a Senior Business leader at Canada's most significant digital health services company – TELUS Health where he led on several multi-million dollar commercialized products and ventures reviews.

Bruce Matichuk, B.Sc, M.Sc. CTO & Director, AI/ML Innovations Inc and Health Gauge

Bruce has been CTO of several AI Tech companies, where he led multiple teams in new AI/ML innovations and raised millions privately.

Nick Watters Independent Director, AI/ML Innovations Inc

Nick is and has been a Director of several public companies and brings an extensive record of Corporate Governance experience. Nick is a co-founder of several successful early stage start up enterprises. He has been an integral part of raising nearly \$260 million for start-up and development opportunities in his career in a wide variety of sectors including mining, high-tech and the biotech industries. Nick is currently Business Development for East Africa Metals Inc.

Dave Cross, CPA Chief Financial Officer, AI/ML Innovations Inc

Dave is a Chartered Professional Accountant, Certified General Accountant, and is a co-founder of Cross Davis & Company, a CPA firm that has focused on providing accounting and management services to publicly listed companies since 2010. In total, Dave has over 23 years of accounting experience, starting in 1997 with a Vancouver-based CPA firm.

OUR TEAM – strategic advisors



Fabrice Pakin, Masters Marketing & International Business *Founder and CEO of Tech2Health*

Fabrice founded Ignilife, a web and mobile SaaS health platform made to empower and engage people to make healthier lifestyle choices. Prior to that, he served as Business Unit Director/Manager for several technology companies.

Dr. Pierre Boulanger, P.Eng , PhD *Advisor to Health Gauge*

Dr. Boulanger is a Professor and Cisco Chair in Healthcare, at the University of Alberta. He holds a double appointment of Professor at the University of Alberta's Department of Computing Science and the Department of Radiology and Diagnostic Imaging. He is also on the editorial board of two major academic journals and sits on several international academic committees. His scientific research topics include new techniques for tele-medicine; patient specific modeling using sensor fusion; the application of tele-presence technologies applied to aged care facilities and remote regions; the application of AR/VR technologies to medical training, simulation, and collaborative diagnostics; and patient-specific modeling in surgery. Dr. Boulanger has accumulated 38 years of experience in 3D computer vision, rapid product development, and the applications of virtual reality systems in medical and industrial manufacturing.

Dr. Jacques Kpodonu, MD, FACC *Advisor to Health Gauge*

Dr. Kpodonu is a triple US boarded cardiac and endovascular surgeon based at the Beth Israel Deaconess Medical Center and surgical faculty at Harvard Medical School. Additionally, he is a visionary clinician, medical scientist, and the lead author and editor of four medical textbooks as well as having regularly published work on topics including digital health, biomedical innovation, design of hybrid operating rooms. Dr. Kpodonu holds leadership roles with the Society of Thoracic Surgery, American College of Cardiology, REACH program and is frequently quoted in national and international journals and media. Dr. Kpodonu's areas of professional expertise and interest include digital health technology, biomedical innovation, innovations in cardiac surgery, global health innovation, and precision medicine.



**AI/ML
INNOVATIONS
INC**

Cap Table (CDN \$)

Shares outstanding:	44,205,518
12-month high/low price:	\$0.23/\$0.03
Current price:	\$0.115
Market Cap:	\$5.1M
Insiders:	20%
Insiders + friends and family	40%

Warrants (ave. price 0.10):	6,712,748
Options (ave. price 0.28):	3,000,000
Proceeds from wts & options:	\$1,511,271
Shares fully diluted:	53,918,266

Metrics 4.17.2023

www.aiml-innovations.com

What We Do & How We Do It

By leveraging the power of leading artificial intelligence and machine-learning tools, we provide for a secure and trusted means for clients to engage clinical resources and health coaching as a regular part of their care process and ongoing health management. Our robust, **real-time data capture and analysis capability provides fast feedback, resulting in better recovery outcomes** and healthy living objectives through the ability to make immediate and better health choices.



Health Gauge Is A Revolutionary New Way To Measure And Track Health Biometrics

**Global Digital Health
Monitoring Market**

**\$245B by 2024 with
39% CAGR**

CORE PROBLEM – health services costs outstripping ability to serve



BP DEVICES ARE INADEQUATE:

- **Current state:** Blood Pressure cuff
- **Problem:** Uncomfortable, not mobile, captures limited information, not wearable, inconvenient
- **Resulting in:** Injury and death due to inadequate handling of hypertension

LIMITED TRACKING AND ANALYSIS:

- **Current state:** Blood Pressure applications
- **Problem:** No personal analysis, no ability to track and analyze personal experience
- **Resulting in:** Poor understanding response to address health conditions. Significant personal and health system costs formation, not wearable, inconvenient

Case study – rising costs of heart disease



100 MILLION

PEOPLE AFFECTED IN NORTH AMERICA



1.5 BILLION

PEOPLE AFFECTED WORLDWIDE



400,000

RELATED DEATHS ANNUALLY IN USA



\$50 BILLION / YR \$

COST TO THE HEALTH SYSTEM



The Seven “Ps” of the Health Gauge Solution

Personalized: Our technology allows both patients and doctors better understand the patient's health by accumulating data combinations that are unique to them (BP, ECG, PPG, HR, HRV, activity, behaviors, sleep, etc) over time.

Precise: Our devices are in the same accuracy range as many monitoring devices used by healthcare providers, in part because of our applied AI and ML.

Predictive: When a patient aggregates hundreds of health metric readings over time on our platform, it's much easier for them and their healthcare team to reach informed conclusions about potential longer term health outcomes, while at the same time micromanaging ongoing therapies daily, hourly or as often as needed.

Preventive: The immediate and actionable feedback provided by our solution to an imminent health problem, coupled with our ability to collect and store years of data about a patient's long-term health or chronic condition is a powerful combination. An informed view of what *could* happen in the future may lead patients to make changes *today*.

Participation: Patients can be involved in their health in a way that has not existed before because of the real-time feedback at their fingertips afforded by our technology. Our wearables, apps and platforms allow patients to participate much more in their own healthcare. The model of healthcare fundamentally shifts from “my doctor tells me what to do once a year” to a model where each patient is a stakeholder in their daily care.


Platform: Our wearables help people get directly involved in their own healthcare in a convenient manner. However, the key is combining our robust data aggregation with our cloud-based platform via phone apps, thus enabling instant, global-scale data integration with clinical patient management protocols and workflows.

Pertinent: The first six “Ps” of the Health Gauge solution collectively have a positive, immediate and relevant influence on patient outcomes, cost of healthcare, and patient-doctor relationships. Patients may now contribute to, and be directly involved in, their healthcare in a way that hasn't existed before, becoming a key contributing member of their healthcare team.

Ultimately, our end-to-end bespoke solution allows patients to participate in their health management with an immediacy and to an extent that was never possible before now.

HEALTH GAUGE VALUE CHAIN: What do we sell?

The value proposition



Health Gauge AI-based personal digital health platform solution

HEALTH GAUGE – PROOF OF CONCEPT STUDY




Bill and Melinda Gates Foundation Funded Study

Study Purpose:

to reduce pregnancy complications and mortality, by making healthcare more accessible using Health Gauge's wearable solution

Conclusion: Health Gauge can help solve important community health problems, affordably

- ✓ HG's AI-driven software for blood pressure estimation helped women better monitor their heart health
- ✓ validated the applicability of the use of HG's technology for helping better identify women at risk of developing eclampsia
- ✓ demonstrated the configurability of the HG Solution, and its ability to be seamlessly integrated into a defined health care plan



HOW WE GET PAID:

Our Current Licensing Contract



HG

Provides technical infrastructure to MedWatch


License Partner

MedWatch Technologies, Inc.

- ✓ US\$120k/year licensing fee
- ✓ 7 year contract (extendable)
- ✓ 2% royalty on MedWatch sales
- ✓ Cost-plus additional service fees
- ✓ US\$2M break fee
- ✓ additional royalties for other software services

MedWatch


Utilizing HG's patented technology to provide non-invasive blood glucose monitoring



End-users

HOW WE GET PAID:

Our Current Channel Partnerships



HG provides package:

\$150 HG-36 Band +
\$25 / subscription
for 12 months



Channel Partners



a leader in the development of innovative, evidence-based tools to improve brain function and enhance athletic performance.



a 12month pilot project to validate the HG solution for athletic performance, with a goal to capitalize on opportunities within the lucrative high-performance athletic market.



a digital health program that uses Cognitive Behavioral Therapy (CBT) techniques to engage users in self-care.

AI On-Call

a partnership to deliver the HG solution for the early prediction, diagnosis, and prevention of sepsis and acute illness in seniors.

Channel Partners:

- provides HG solution
to Payers / Benefits providers
Clients (employer programs)

End Users



End-users:

access via
Benefits programs OR
through their Health
Benefit Providers



Corporate mental wellness support

Qookka Live

B2B subscription model
secure and easy access to personalized programs that include teleconsultations with psychologists and live wellness sessions with certified coaches, with a focus on employee mental health services for corporate clientele.

Qookka DTx

B2C and B2B2C model
a secure digital mental health therapy platform for high chronic anxiety and depressive patients, administered by a psychiatrist.



RPM Platform

B2B subscription model
a full stack SaaS digital therapy and remote patient monitoring platform that allows hospitals and clinics to easily commence a “no code” value-based care program with their patients.



The Case for Digital **Mental** Healthcare

“The global digital mental health software market is expected to reach **US\$ 21.9 billion** by 2027, with the global digital mental health market expected to ascend at a **CAGR of 28.6%** from 2021-2027” (QuantAlign Research)

“The economic case for investment in mental health is strong: for every **\$1 invested** in scaled-up treatment for depression and anxiety, there is a **\$4 return** in better health and productivity” (WHO)

“Since the start of the COVID-19 pandemic, some **42 percent of employees** globally have reported a decline in mental health” (McKinsey & Company)

“Almost **1 billion people** worldwide suffer from a mental disorder. Lost productivity resulting from anxiety and depression costs the global economy **US\$1 trillion** each year” (WHO)

“Poor mental health is projected to cost the world economy **US\$6 trillion** by 2030 in poor health and reduced productivity” (The Lancet)





Tech2Heal's Founders generated historical revenues of US\$4.2 million, providing mental health services to these leading insurers



AI/ML's growth strategy

- continued accretive, synergistic acquisitions in the digital healthcare space



growth plan

- Initial focus on North American markets
- Pilot programs with B2B channel partners being readied
- Product use/sales discussions with Primary Care facilities, academic facilities, diagnostic companies, insurers
- Class 2 FDA 510k medical device clearance in works
- Additional resources to be deployed on business development
- Additional capacity for supply chain & inventory
- AI validation in works
- Possibility to leverage Tech2Health client base needs



growth plan

- Organic growth in EU through historical network
- Leverage existing sales network in South America
- Robust marketing plan in place
- Pilot projects for its RPM Platform being readied with several interested parties
- Market opportunity in USA, in discussion with large healthcare provider



PRIVATE & CONFIDENTIAL

Public Company Comparables (1.17.23 – Yahoo Finance)

Company (in CAD)	Market Cap	Share Price	Revenue (TTM)	EPS (TTM)
WELL Health Tech	846.5M	3.71	528.3M	-0.23
CloudMD	68.9M	0.235	148.9M	-0.15
Vitalhub	127.4M	2.95	35.6M	-0.05
Reliq Health	114.1M	0.59	10.4M	-0.04
Fobi AI	38.5M	0.25	2.0M	-0.14
VentriPoint Diag.	42.3M	0.265	40.0M	-0.03
Empower Clinics	9.1M	0.03	5.4M	-0.10

THANK YOU FOR YOUR TIME

MARCH 2023
PRIVATE &
CONFIDENTIAL

For detailed information please see AI/ML's website at <https://aiml-innovations.com/>
or the Company's filed documents at www.sedar.com.

For further information:

Blake Fallis at (778) 405-0882 blake.fallis@aiml-innovations.com
or info@aiml-innovations.com.

Presentations:

Corporate video: <https://www.youtube.com/watch?v=k2QSjo7clXc&feature=youtu.be>

Official YouTube Channel: https://www.youtube.com/channel/UCCfOj2P_Fu3TOK6Jl1G9vEQ

www.aiml-innovations.com



CSE: AIML
OTCQB: AIMLF
FWB: 42FB

Investing in Tomorrow's Technology - Today